Minoryx Therapeutics
8 known investors
Minoryx is a biopharmaceutical company that discovers and develops drug treatments for severe orphan diseases of the central nervous system, such as cerebral adrenoleukodystrophy and Rett syndrome. Its lead candidate, leriglitazone, is being evaluated in clinical trials and regulatory review for these rare CNS conditions.
Investors · 8
Chiesi VenturesBoston · $5M
Criteria Bio VenturesBarcelona
Fund+Leuven · $5.5M – $16.5M
Invivo Capital PartnersBarcelona · $2.2M – $4.3M
Kurma PartnersParis · $162K – $10.8M
Roche Venture FundBasel · $648K – $3.2M
Ysios CapitalBarcelona · $5.4M – $21.6M
Columbus Venture PartnersreportedValenciavia Jose Mesa · inferred
Frequently asked questions
- What does Minoryx Therapeutics do?
- Minoryx is a biopharmaceutical company that discovers and develops drug treatments for severe orphan diseases of the central nervous system, such as cerebral adrenoleukodystrophy and Rett syndrome. Its lead candidate, leriglitazone, is being evaluated in clinical trials and regulatory review for these rare CNS conditions.
- Who are Minoryx Therapeutics's investors?
- Minoryx Therapeutics's investors include Chiesi Ventures, Criteria Bio Ventures, Fund+, Invivo Capital Partners, Kurma Partners, Roche Venture Fund, Ysios Capital, Columbus Venture Partners.